{"DataElement":{"publicId":"7409540","version":"1","preferredName":"Surgical Tumor Tissue Anticipated CPTAC Neoplasm Other Specify","preferredDefinition":"An explanation different than the one(s) previously specified of the anticipated CPTAC tissue type assigned to a malignant neoplasm sample that was surgically removed from an organ.","longName":"7409538v1.0:6832577v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7409538","version":"1","preferredName":"Surgical Tumor Tissue Anticipated CPTAC Neoplasm","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._A tumor sample, or entire tumor that is removed for microscopic examination._Considered likely or probable; anticipated._A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"7409535v1.0:7409536v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"7409535","version":"1","preferredName":"Surgical Procedure Tumor Tissue","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.:A tumor sample, or entire tumor that is removed for microscopic examination.","longName":"C15329:C18009","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Tissue Sample","conceptCode":"C18009","definition":"Tissue sample that contains an abnormal cellular infiltrate forming a solid mass. The abnormal cellular component can be benign or malignant. Tumor samples are obtained for microscopic examination and/or molecular analysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADE3BA57-4CCB-550B-E053-4EBD850A026F","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"ONEDATA","dateModified":"2020-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7409536","version":"1","preferredName":"Expected Clinical Proteomic Tumor Analysis Consortium Neoplasm","preferredDefinition":"Considered likely or probable; anticipated.:A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C25501:C157175:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Expected","conceptCode":"C25501","definition":"Considered likely or probable; anticipated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADE3BA57-4CDD-550B-E053-4EBD850A026F","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"ONEDATA","dateModified":"2020-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ADE3BA57-4CEE-550B-E053-4EBD850A026F","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeDescription":"1/26/21 jk Released per SME (NGM) review and approval. 8/27/20 jk created for Solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6832577","version":"1","preferredName":"Other Specify","preferredDefinition":"Different than the one(s) previously specified or mentioned._Be specific about something; define clearly.","longName":"OTH_SPEC","context":"OCCPR","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208051","version":"1","preferredName":"Other Specify","preferredDefinition":"Not otherwise specified.:Specify; be specific about something; define clearly.","longName":"C17649:C25685","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Specify","conceptCode":"C25685","definition":"Be specific about something; define clearly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3B5E-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"8E9A3B10-BC5A-67B5-E053-F662850A6556","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-07-26","modifiedBy":"KNABLEJ","dateModified":"2019-08-19","changeDescription":"8/19/19 jk released for reuse by Theradex.  7/26/19 jk created for use on multiple CPTAC CRF questions.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"7409064","version":"1","longName":"All Procurement CRFs","context":"OCCPR"},{"publicId":"7409065","version":"1","longName":"Solid Tumor Specimen","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If Other, specify","type":"Preferred Question Text","description":"If Other, specify","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"ADE3DB76-419D-5505-E053-4EBD850AD0D3","latestVersionIndicator":"Yes","beginDate":"2020-08-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2020-08-27","modifiedBy":"KNABLEJ","dateModified":"2021-01-26","changeDescription":"1/26/21 jk Released, upd Reg Status per SME (NGM) review and approval. 10/8/20 jk replaced system generated definition.  8/27/20 jk created for solid tumor procurement CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}